About: Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $18.39 (+1.38%)
RCUS NYSE Arcus Biosciences Inc
Arcus Biosciences Inc share price
Atividade de preço de RCUS
Último preço
$ 18,430
Variação (24h)
0,29 USD (1,60%)
Volume
2.02M
Volume (média 4 sem.)
-
Abertura
$ 17,85
Variação do dia
$ 17,77 - $ 18,51
Fechamento anterior
$ 18,14
Último negócio
28 Oct, 8:00 pm GMT+0
Atrasado
28 Oct, 8:00 pm GMT+0
RCUS price performance
Atrasado
28 Oct, 8:00 pm GMT+0
quote.marketSignals